ArticleNanomedicine : nanotechnology, biology, and medicine2020
A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- RNA-DNA Fusomer Fibers With Customizable Physicochemical, Mechanical, and Biological Properties for Next-Generation Therapeutics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Immunostimulatory nucleic acid nanoparticles establish antiviral state to inhibit viral infection and replication.Journal of virology · 2026Article
- Engineering Optimized EV-Mimetic Carriers for Efficient Tumor-Targeted Delivery of Functional RNA Nanoparticles.ACS nano medicine · 2026Article
- Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral-Like Immunomodulatory Responses and Potent Adjuvant Activity.Advanced functional materials · 2026Article
- Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer.ACS applied materials & interfaces · 2025Article
- From Sequence to Response: AI-Guided Prediction of Nucleic Acid Nanoparticles Immune Recognitions.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Nucleic Acid Nanoparticles Redefine Traditional Regulatory Terminology: The Blurred Line between Active Pharmaceutical Ingredients and Excipients.ACS nano medicine · 2025Article
- Changes in Generations of PAMAM Dendrimers and Compositions of Nucleic Acid Nanoparticles Govern Delivery and Immune Recognition.ACS biomaterials science & engineering · 2025Article
- Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.RNA nanomed · 2025Article
- Autonomous Nucleic Acid and Protein Nanocomputing Agents Engineered to Operate in Living Cells.ACS nano · 2025Review
- Leveraging plant-derived nanovesicles for advanced nucleic acid-based gene therapy.Theranostics · 2025Review
- Immunostimulatory nucleic acid nanoparticles (NANPs) augment protective osteoblast and osteoclast type I interferon responses to Staphylococcus aureus.Nanomedicine : nanotechnology, biology, and medicine · 2024Article
- Design and Characterization of Compact, Programmable, Multistranded Nonimmunostimulatory Nucleic Acid Nanoparticles Suitable for Biomedical Applications.Biochemistry · 2024Article
- The Reduction of Traumatic Spinal Cord Secondary Injury by Anti-RhoA siRNA Functionalized Nucleic Acid Nanoparticles (NANPs).RNA nanomed · 2024Article
- Polymeric Vehicles for Nucleic Acid Delivery: Enhancing the Therapeutic Efficacy and Cellular Uptake.Recent advances in drug delivery and formulation · 2024Review
- Nanoscale metal-organic frameworks for the delivery of nucleic acids to cancer cells.International journal of pharmaceutics: X · 2023Article
- Advances in modification and delivery of nucleic acid drugs.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023Review
- Light-Assisted Drying for the Thermal Stabilization of Nucleic Acid Nanoparticles and Other Biologics.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles.Frontiers in immunology · 2023Review
- Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Programmable nucleic acid nanoparticles (NANPs) provide controlled coordination of therapeutic nucleic acids (TNAs) and other biological functionalities. Beyond multivalence, recent reports demonstrate that NANP technology can also elicit a specific immune response, adding another layer of customizability to this innovative approach. While the delivery of nucleic acids remains a challenge, new carriers are introduced and tested continuously. Polymeric platforms have proven to be efficient in shielding nucleic acid cargos from nuclease degradation while promoting their delivery and intracellular release. Here, we venture beyond the delivery of conventional TNAs and combine the stable cationic poly-(lactide-co-glycolide)-graft-polyethylenimine with functionalized NANPs. Furthermore, we compare several representative NANPs to assess how their overall structures influence their delivery with the same carrier. An extensive study of various formulations both in vitro and in vivo reveals differences in their immunostimulatory activity, gene silencing efficiency, and biodistribution, with fibrous NANPs advancing for TNA delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.